Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MigrA Zero
- Development stage
- Unknown
- Lead developer
- Iconis Bioceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MigrA Zero is a multi-ingredient dietary supplement developed by Iconis Bioceuticals for the prevention and relief of migraine headaches. The formula combines four active ingredients: PA-free butterbur extract, CoEnzyme Q10, magnesium glycinate, and riboflavin (vitamin B2). These components are intended to support neurological function through several mechanisms, including the reduction of blood vessel inflammation, stabilization of nerve membranes, and enhancement of mitochondrial cellular energy production. It is marketed as a natural alternative to prescription pharmaceuticals and is typically administered as four capsules daily.
- Brand names
- MigrA Zero
Beyond the preview
Go deeper on MigrA Zero.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MigrA Zero.